The Danish pharmaceutical giant’s commanding position in the weight-loss drug market is under significant threat. Novo Nordisk, already contending with a disappointing annual forecast, now faces direct competition for its blockbuster drug Wegovy. As the initial hype subsides, a fierce battle over pricing appears imminent.<\/p>\n
The company’s challenges were underscored in early February when it issued a sobering outlook for the current fiscal year, unsettling investors. Key concerns from the guidance include:<\/p>\n
Declining Revenue: On a currency-adjusted basis, sales are projected to fall between 5% and 13%.
\nIntensifying Competition: Management identified aggressive competition and price concessions in the critical U.S. market as primary drivers of the pressure.
\nMargin Erosion: The anticipated arrival of lower-cost generic alternatives in international markets presents a further risk to profitability.<\/p>\n
This gloomy financial backdrop sets the stage for the latest competitive development.<\/p>\n
Indian Pharma Giant Launches Generic Challenge<\/p>\n
In a move that signals a new era for the GLP-1 drug market, India’s Dr. Reddy’s Laboratories has announced plans to introduce a generic version of the popular weight-loss injection Wegovy. The timing is strategic: the patent for the active ingredient semaglutid is set to expire in India in March 2026. This will strip Novo Nordisk of its exclusive protection in one of the world’s most populous markets.<\/p>\n